CCO Independent Conference Highlights of the 2023 ASCO Annual Meeting

Review slidesets, an on-demand webcast, and expert analyses of key data from the 2023 Clinical Oncology Annual Scientific Meeting!

Share

Program Content

Activities

Key Studies from Chicago 2023
An Expert’s Guide to ASCO 2023: Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2023

11 Capsule Summary Slides

Activities

PHERGain
PHERGain: 3-Yr iDFS Results From the Phase II Trial of Chemotherapy De‑escalation in HER2+ Early Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

NATALEE
NATALEE: Phase III Trial of Adjuvant Ribociclib + Nonsteroidal Aromatase Inhibitor vs Nonsteroidal Aromatase Inhibitor Alone for HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

SOFT: Prognostic/Predictive Analyses
Evaluation of the Prognostic and Predictive Value of PAM50 Intrinsic Subtypes and ROR Scores in Premenopausal Women With HR+/HER2- Early Breast Cancer Enrolled in the SOFT Trial
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2023

monarchE Subgroup Analysis by Age
monarchE Subgroup Analysis by Age: Adjuvant Abemaciclib + ET in Older vs Younger Patients With High-Risk, Node-Positive HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

T-DXd Efficacy/Safety: Age Analysis
Pooled Analysis of Trastuzumab Deruxtecan Efficacy and Safety by Age in Patients With HER2+ Metastatic Breast Cancer From DESTINY-Breast01, 02, and 03 Trials
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

SONIA
SONIA: Phase III Trial Assessing the Optimal Therapeutic Position of CDK4/6 Inhibitors for Patients With HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

Ovarian Ablation/Suppression in BC
EBCTCG Meta-analysis of Breast Cancer Recurrence and Survival Following Ovarian Ablation or Suppression in Premenopausal Women
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

HER3-DXd in HER2- Breast Cancer
Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HER2-Negative Metastatic Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

PALMIRA
Phase II PALMIRA: Second-line ET ± Palbociclib Maintenance in Patients With HR+/HER2- Advanced Breast Cancer After Clinical Benefit on First-line Palbociclib + ET
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

TROPiCS-02 Final Analysis
TROPiCS-02: Final OS Analysis of the Phase III Trial of Sacituzumab Govitecan vs Treatment of Physician’s Choice in HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2023

PADA-1 Update
Phase III PADA-1 Update: Palbociclib + Switching to Fulvestrant vs Continuing AI Therapy in ER+/HER2- MBC With Rising ESR1 Mutations by ctDNA Analysis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2023

Activities

ASCO to Clinic: Breast Cancer
Conference to Clinic: Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2023

Conference to Clinic: Breast Cancer
Conference to Clinic: Expert Analysis of the Top Breast Cancer Abstracts From the 2023 Oncology Meeting in Chicago
Video
Congratulations: You achieved a completion on 04/09/2022

Released: July 03, 2023

Expires: July 02, 2024

ASCO 2023 Breast Cancer
Key Studies in Breast Cancer: Independent Conference Coverage of the 2023 ASCO Annual Meeting
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 18, 2023

Expires: August 17, 2024

8 Capsule Summary Slides

Activities

ATTRACTION-5
ATTRACTION-5: Phase III Study of Adjuvant Nivolumab + Chemotherapy After Gastrectomy for Pathologic Stage III Gastric or Gastroesophageal Junction Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

NORPACT-1
NORPACT-1: Neoadjuvant FOLFIRINOX vs Upfront Surgery in Resectable Pancreatic Head Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

KEYNOTE-966 HRQoL
KEYNOTE-966: Health-Related Quality-of-Life Outcomes With Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Advanced Biliary Tract Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2023

Tucatinib + Trastuzumab in HER2+ BTC
Tucatinib + Trastuzumab for Previously Treated Advanced HER2+ Biliary Tract Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

Zanidatamab for HER2+ BTC
HERIZON-BTC-01: Zanidatamab, a HER2-Targeted Bispecific Antibody, in Previously Treated HER2‑Amplified Biliary Tract Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

AtezoTRIBE Update
AtezoTRIBE: Updated Results of First-line Treatment With FOLFOXIRI + Bevacizumab ± Atezolizumab for Unresectable Metastatic Colorectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

PROSPECT
PROSPECT: Neoadjuvant Chemoradiation vs FOLFOX With Selective Chemoradiation for Locally Advanced Rectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

FIRE-4 Liquid Biopsy Analysis
FIRE-4: RAS/BRAF Mutation by Liquid Biopsy and Benefit From First-line FOLFIRI + Cetuximab in Patients With RAS-WT Metastatic Colorectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2023

Activities

Conference to Clinic: Gastrointestinal Cancers
Conference to Clinic: Gastrointestinal Cancers
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 20, 2023

Conference to Clinic: Gastrointestinal Malignancies
Conference to Clinic: Expert Analysis of the Top Gastrointestinal Malignancies Abstracts From the 2023 Oncology Meeting in Chicago
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 29, 2023

Expires: June 28, 2024

ASCO 2023 GI Cancers
Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2023 ASCO Annual Meeting
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 29, 2023

Expires: August 28, 2024

6 Capsule Summary Slides

Activities

KEYNOTE-826 Final Analysis
KEYNOTE-826: Final OS Analysis of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Persistent, Recurrent, or Metastatic Cervical Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

MIRASOL
MIRASOL: Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in FRα-High Expression, Platinum-Resistant Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

SHAPE
SHAPE: Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Low-Risk Early-Stage Cervical Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

DUO-O
DUO-O: First-line CT + Bevacizumab ± Durvalumab Followed by Maintenance Bevacizumab ± Durvalumab With or Without Olaparib in Newly Diagnosed Advanced Ovarian Cancer Without Tumor BRCA Mutation
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

RUBY: HRQoL With Dostarlimab + CP in EC
ENGOT-EN6-NSGO/GOG-3031/RUBY: PROs With Addition of Dostarlimab to  Carboplatin/Paclitaxel for Advanced or Recurrent Endometrial Cancer
Capsule Summary
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

RUBY Dostarlimab + CT
ENGOT-EN6-NSGO/GOG3031/RUBY: Outcomes by BICR With Addition of Dostarlimab to Carboplatin/Paclitaxel for Advanced or Recurrent Endometrial Cancer
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Activities

ASCO to Clinic: Gynecologic Cancer
Conference to Clinic: Gynecologic Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 20, 2023

Conference to Clinic: Gynecologic Cancers
Conference to Clinic: Expert Analysis of the Top Gynecologic Cancer Abstracts From the 2023 Oncology Meeting in Chicago
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 29, 2023

Expires: June 28, 2024

EA: Top Gyn Cancer Abstracts
Conference to Clinic: Expert Analysis of the Top Gynecologic Cancer Studies From the 2023 Oncology Meeting in Chicago
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 03, 2023

Expires: August 02, 2024

16 Capsule Summary Slides

Activities

Glofitamab in R/R LBCL
Extended Follow-up and Landmark Analyses From Pivotal Phase II Trial of Glofitamab in R/R LBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

COMMANDS
COMMANDS: Luspatercept vs Epoetin alfa for ESA-Naive Transfusion-Dependent Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

IMerge
IMerge: Phase III Trial of Imetelstat vs Placebo for Transfusion-Dependent Lower-Risk MDS Relapsed/Refractory to ESAs
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2023

Elranatamab After BCMA Therapy in R/R MM
Elranatamab Monotherapy for R/R MM After Previous BCMA-Directed Therapy: Pooled Analysis of MagnetisMM Studies
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

JACKPOT8
JACKPOT8 Part B: Pivotal Phase II Study of Golidocitinib, a JAK1-Selective Inhibitor, in Relapsed/Refractory PTCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Phase I PHE885 CAR T-Cell
Phase I: BCMA-Targeted PHE885 CAR T-Cell Therapy With Rapid Manufacturing Time for R/R Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

MajesTEC-1 Update: Teclistamab in R/R MM
MajesTEC-1 Update: Phase I/II Study of Teclistamab in Patients With R/R MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

CPX-351 vs 7+3: Cardiotoxicity
Cardiotoxicity of CPX-351 vs 7+3 in Previously Untreated High-Risk or Secondary AML: Post Hoc Analysis of a Pivotal Phase III Trial
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

EPCORE NHL-1 Update
EPCORE NHL-1 Update: Pivotal Phase I/II Trial of Epcoritamab in Patients With R/R B-Cell NHL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

KEYNOTE-667
KEYNOTE-667 High-Risk Group Update: Pembrolizumab + COPDAC-28 Consolidation in Children and AYA cHL
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

BRUIN 2-Yr Update
BRUIN 2-Yr Update: Phase I/II Trial Evaluating Pirtobrutinib in Covalent BTKi–Treated MCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

CARTITUDE-1 Update
CARTITUDE-1 Update: Phase I/II Trial of Ciltacabtagene Autoleucel for Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

TRANSCEND CLL 004
TRANSCEND CLL 004: Phase I/II Trial of Lisocabtagene Maraleucel for Relapsed/Refractory CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

CARTITUDE-4 With Cilta-Cel vs SoC
CARTITUDE-4: Phase III Trial of Ciltacabtagene Autoleucel vs SoC for Lenalidomide-Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

SWOG S1826
SWOG S1826: Phase III Trial of Nivolumab + AVD vs Brentuximab Vedotin + AVD for Newly Diagnosed Advanced cHL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

Alliance A041703
Alliance A041703: Phase II Trial of Inotuzumab Ozogamicin Induction Followed by Blinatumomab Consolidation for Older Adults With Newly Diagnosed Ph-Negative, CD22-Positive B-ALL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

Activities

Multiple Myeloma
Conference to Clinic: Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2023

Conference to Clinic: Leukemias
Conference to Clinic: Leukemias
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2023

ASCO 2023: Lymphomas and CLL
Conference to Clinic: Lymphomas and CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2023

Conference to Clinic: Hematologic Malignancies
Conference to Clinic: Expert Analysis of the Top Hematologic Malignancies Abstracts From the 2023 Oncology Meeting in Chicago
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 29, 2023

Expires: June 28, 2024

ASCO 2023: Hematologic Malignancies
Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2023 ASCO Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 25, 2023

Expires: August 24, 2024

12 Capsule Summary Slides

Activities

Neoadjuvant Osimertinib in EGFRm NSCLC
Phase II Trial of Neoadjuvant Osimertinib in Stage I-IIIA EGFR-Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

AGAIN
Phase III AGAIN (JCOG1404/WJOG8214L) Trial: First-line EGFR-TKI Monotherapy vs EGFR-TKI and Inserted Cisplatin/Pemetrexed in Advanced Nonsquamous, EGFR-Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

NEOTORCH
Phase III NEOTORCH: Interim EFS Analysis of Perioperative Toripalimab + Platinum-Doublet CT vs Platinum-Doublet CT in Resectable Stage II/III NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2023

Pembro + CT in Pleural Mesothelioma
Phase III Trial of Pembrolizumab + Chemotherapy vs Chemotherapy Alone in Treatment-Naive Pleural Mesothelioma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

TROPION-Lung02
TROPION-Lung02: Datopotamab Deruxtecan + Pembrolizumab ± Platinum Chemotherapy in Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

KEYNOTE-671
KEYNOTE-671: Pembrolizumab or Placebo + Platinum-Based Neoadjuvant Chemotherapy Followed by Resection and Adjuvant Pembrolizumab or Placebo in Early-Stage NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

CheckMate 9LA: 4-Yr Update
CheckMate 9LA: 4-Yr Update of First-line Nivolumab + Ipilimumab + CT vs CT Alone in Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

ADAURA: Final OS Analysis
ADAURA: OS Analysis of Adjuvant Osimertinib vs Placebo After Complete Resection in Stage IB-IIIA EGFR-Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

KEYNOTE-789
Phase III KEYNOTE-789: Pemetrexed/Platinum Chemotherapy ± Pembrolizumab in TKI-Resistant, EGFR-Mutated, Metastatic Nonsquamous NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

SWOG S1929
Phase II SWOG S1929: Maintenance Atezolizumab ± Talazoparib for SLFN11-Positive Extensive-Stage SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

INSIGHT 2 Trial Results
INSIGHT 2: Tepotinib + Osimertinib for Advanced EGFR-Mutated NSCLC With MET Amplification Following First-line Osimertinib
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

LUNAR: TTFields in NSCLC
Phase III LUNAR: Tumor Treating Fields + Standard Second-line Therapy in Metastatic NSCLC With Progression On/After Platinum-Based Therapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

Activities

Conference to Clinic: Lung Cancer
Conference to Clinic: Lung Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2023

Conference to Clinic: Lung Cancer
Conference to Clinic: Expert Analysis of the Top Lung Cancer Abstracts From the 2023 Oncology Meeting in Chicago
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 29, 2023

Expires: June 28, 2024

Lung Cancer Highlights: ASCO 2023
Key Studies in Lung Cancer: Independent Conference Coverage of ASCO 2023
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 25, 2023

Expires: August 24, 2024

6 Capsule Summary Slides

Activities

RELATIVITY-047 2-Yr Update
RELATIVITY-047: 2-Yr Update of First-line Nivolumab + Relatlimab vs Nivolumab in Advanced Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

Adjuvant mRNA-4157 + Pembro in Melanoma
Phase II KEYNOTE-942: DMFS With Adjuvant mRNA-4157 (V940) + Pembrolizumab vs Pembrolizumab in Resected High-Risk Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

Fianlimab/Cemiplimab in Adv Melanoma
Phase I Trial of Fianlimab (Anti‒LAG-3 mAb) + Cemiplimab (Anti‒PD-1 mAb) in Patients With Advanced Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

OpACIN-neo and PRADO
OpACIN-neo and PRADO: Effect of Response-Directed Treatment Personalization on Survival After Neoadjuvant Immune Checkpoint Blockade in Stage III Melanoma
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

CheckMate 76K: Biomarker Analysis
Biomarker Analysis From CheckMate 76K Phase III Trial of Adjuvant Nivolumab vs Placebo in High-Risk Stage IIB/C Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

KEYNOTE-716: DMFS and RFS Update
Phase III KEYNOTE-716 Update: Final DMFS Analysis of Adjuvant Pembrolizumab vs Placebo in Stage IIB/IIC Melanoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2023

Activities

Conference to Clinic Melanoma
Conference to Clinic: Melanoma and Other Skin Cancers
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2023

Conference to Clinic: Melanoma and Other Skin Cancers
Conference to Clinic: Expert Analysis of the Top Melanoma and Other Skin Cancers Abstracts From the 2023 Oncology Meeting in Chicago
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 29, 2023

Expires: June 28, 2024

ASCO 2023: Key Melanoma Studies
Key Studies in Skin Cancer: Independent Conference Coverage of the 2023 ASCO Annual Meeting
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 21, 2023

Expires: August 20, 2024

Faculty

cover img faculity

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

cover img faculity

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

cover img faculity

Jason J. Luke, MD, FACP

Associate Professor
Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

cover img faculity

Lauren Prescott, MD, MPH

Assistant Professor, Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

cover img faculity

Karen Reckamp, MD, MS

Professor in Medicine
Director, Division of Medical Oncology
Associate Director, Clinical Research
Cedars-Sinai Medical Center
Los Angeles, California

cover img faculity

Ritu Salani, MD, MBA

Professor and Division Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, California

cover img faculity

Jeffrey P. Sharman, MD

Medical Director
Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

cover img faculity

Rachna Shroff, MD, MS

Professor of Medicine
Interim Chief, Division of Hematology/Oncology
University of Arizona Cancer Center
Tucson, Arizona

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Heather Wakelee, MD, FASCO

Professor of Medicine
Department of Medicine/Oncology
Stanford University
Stanford University Cancer Institute
Stanford, California 

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

cover img faculity

Jeffrey S. Weber, MD, PhD

Professor of Medicine
NYU Grossman School of Medicine
Deputy Director
NYU Langone Health
Laura and Isaac Perlmutter Cancer Center
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, Geron, Gilead, GSK, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp, Novartis, Novocure, Regeneron Pharmaceuticals, Inc., and Seagen.

AbbVie

AstraZeneca

Daiichi Sankyo

Geron

Gilead

GSK

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis

Novocure

Regeneron Pharmaceuticals, Inc

Seagen